HC Wainwright 将Altimmune(ALT)的“Buy”评级维持在12美元, HC Wainwright maintains "Buy" rating for Altimmune (ALT) at $12.00 despite negative ROE and net margin.

HC Wainwright 重申 Altimmune （ALT） 的“买入”评级为 12.00 美元，尽管在最近的收益报告中，ROE 和净利润率为负。 HC Wainwright reaffirms "Buy" rating for Altimmune (ALT) at $12.00, despite negative ROE and net margin in recent earnings report. Altimmune的主要产品候选者Pemvidutide正在第二阶段试验肥胖症和新陈代谢性机能障碍相关肝炎,分析员的目标平均价格为18.80美元。 Altimmune's lead product candidate, pemvidutide, is in Phase 2 trials for obesity and metabolic dysfunction-associated steatohepatitis, with an average analyst target price of $18.80. 该公司面临市场上限低和贝塔等挑战,以及内幕混合交易;然而,许多分析家对股票仍然持肯定态度。 The company faces challenges in terms of low market cap and beta, along with mixed insider transactions; however, multiple analysts remain positive about the stock.